Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniela Cristina Vitale

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
European Journal of Drug Metabolism and Pharmacokinetics|March 31, 2011
Human pharmacokinetics of the muscle relaxant, eperisone hydrochloride by liquid chromatography-electrospray tandem mass spectrometryBarbara Melilli, Cateno Piazza, Daniela Cristina Vitale, et al.
Cancers|January 11, 2022
Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia: Are Supporting Evidences Enough?Serena Brancati, Lucia Gozzo, Giovanni Luca Romano, et al.
Journal of Clinical Medicine|July 29, 2025
Length of Washout Period After Remission Does Not Influence Relapse Risk in Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents Combined with VenetoclaxFanny Erika Palumbo, Andrea Duminuco, Laura Longo, et al.
Journal of Clinical Medicine|August 14, 2025
Does the Timing of Response Impact the Outcome of Relapsed/Refractory Acute Myeloid Leukemia Treated with Venetoclax in Combination with Hypomethylating Agents? A Proof of Concept from a Monocentric Observational StudyErmelinda Longo, Fanny Erika Palumbo, Andrea Duminuco, et al.
Frontiers in Pharmacology|December 13, 2021
Off-Label Use of Venetoclax in Patients With Acute Myeloid Leukemia: Single Center Experience and Data From Pharmacovigilance DatabaseLucia Gozzo, Calogero Vetro, Serena Brancati, et al.
Healthcare (Basel, Switzerland)|May 27, 2023
Severe Gastrointestinal Toxicity Following the Use of Gilteritinib: A Case Series and Analysis of Postmarketing Surveillance DataLucia Gozzo, Antonella Nardo, Serena Brancati, et al.
Journal of Clinical Medicine|July 27, 2024
Early Access for Medicines in ITALY: The Case of Ruxolitinib for Patients with Graft-Versus-Host DiseaseLucia Gozzo, Salvatore Leotta, Giovanni Luca Romano, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
European Journal of Drug Metabolism and Pharmacokinetics|March 31, 2011
Human pharmacokinetics of the muscle relaxant, eperisone hydrochloride by liquid chromatography-electrospray tandem mass spectrometryBarbara Melilli, Cateno Piazza, Daniela Cristina Vitale, et al.
Cancers|January 11, 2022
Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia: Are Supporting Evidences Enough?Serena Brancati, Lucia Gozzo, Giovanni Luca Romano, et al.
Journal of Clinical Medicine|July 29, 2025
Length of Washout Period After Remission Does Not Influence Relapse Risk in Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents Combined with VenetoclaxFanny Erika Palumbo, Andrea Duminuco, Laura Longo, et al.
Journal of Clinical Medicine|August 14, 2025
Does the Timing of Response Impact the Outcome of Relapsed/Refractory Acute Myeloid Leukemia Treated with Venetoclax in Combination with Hypomethylating Agents? A Proof of Concept from a Monocentric Observational StudyErmelinda Longo, Fanny Erika Palumbo, Andrea Duminuco, et al.
Frontiers in Pharmacology|December 13, 2021
Off-Label Use of Venetoclax in Patients With Acute Myeloid Leukemia: Single Center Experience and Data From Pharmacovigilance DatabaseLucia Gozzo, Calogero Vetro, Serena Brancati, et al.
Healthcare (Basel, Switzerland)|May 27, 2023
Severe Gastrointestinal Toxicity Following the Use of Gilteritinib: A Case Series and Analysis of Postmarketing Surveillance DataLucia Gozzo, Antonella Nardo, Serena Brancati, et al.
Journal of Clinical Medicine|July 27, 2024
Early Access for Medicines in ITALY: The Case of Ruxolitinib for Patients with Graft-Versus-Host DiseaseLucia Gozzo, Salvatore Leotta, Giovanni Luca Romano, et al.
Pageof 2